COMPANY
Arima Genomics, Inc.
Timeline
- Partnership Partnership / licensing announced Jul 2, 2026. Source: company's own press page. source ↗
Funding
- Partnership / licensing announced Jul 2, 2026. Source: company's own press page. source ↗
NIH awards 22
- NIH award 5R44CA247185-04 FY2024: $1,913,603 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Developing a kit-based research use on source ↗
- NIH award 5R44GM149103-02 FY2024: $1,084,321 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Scalable single-cell workflow for multio source ↗
- NIH award 2R44CA247185-03A1 FY2023: $2,069,712 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Developing a kit-based research use source ↗
- NIH award 1R44GM149103-01 FY2023: $1,013,363 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Scalable single-cell workflow for multio source ↗
- NIH award 5R44HG011897-02 FY2022: $1,015,129 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. A scalable kit-based assay for multi-omi source ↗
- NIH award 5R44GM142410-02 FY2022: $982,776 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. A low-input compatible, end-to-end kitted source ↗
- NIH award 1R44HG011897-01 FY2021: $1,085,125 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. A scalable kit-based assay for multi-omi source ↗
- NIH award 1R44GM142410-01 FY2021: $1,074,115 awarded for that fiscal year; activity R44 (SBIR); PI SCHMITT, ANTHONY; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. A low-input compatible, end-to-end kitte source ↗
- NIH award 5R44CA247185-02 FY2021: $999,273 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of a highly-sensitive, source ↗
- NIH award 1R44CA247185-01 FY2020: $999,273 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of a highly-sensitive, source ↗
- NIH award 5R44HG008118-05 FY2019: $174,249 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of HaploSeq as a Servi source ↗
- NIH award 5R44HG009584-02 FY2018: $928,154 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of a low-cost user-fri source ↗
- NIH award 2R44HG008118-04A1 FY2018: $1,573,140 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of HaploSeq as a S source ↗
- NIH award 1R44HG009584-01 FY2017: $848,530 awarded for that fiscal year; activity R44 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Commercialization of a low-cost user-fri source ↗
- NIH award 3R43AI124837-01A1S1 FY2017: $49,539 awarded for that fiscal year; activity R43 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Maximal resolution and full-length pha source ↗
- NIH award 6R41HG008118-03 FY2016: $43,503 awarded for that fiscal year; activity R41 (STTR); PI HEINTZMAN, NATE; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Optimizing HaploSeq for whole-genome phased source ↗
- NIH award 3R41HG008118-02S1 FY2016: $30,076 awarded for that fiscal year; activity R41 (STTR); PI HEINTZMAN, NATE; recipient as written: ARIMA GENOMICS, INC., SAN DIEGO, CA. Optimizing HaploSeq for whole-genome phase source ↗
- NIH award 1R43AI124837-01A1 FY2016: $224,576 awarded for that fiscal year; activity R43 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Maximal resolution and full-length phas source ↗
- NIH award 1R43HD087113-01A1 FY2016: $290,577 awarded for that fiscal year; activity R43 (SBIR); PI SELVARAJ, SIDDARTH; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Non-invasive determination of complete source ↗
- NIH award 5R41HG008118-02 FY2016: $379,725 awarded for that fiscal year; activity R41 (STTR); PI HEINTZMAN, NATE; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Optimizing HaploSeq for whole-genome phased source ↗
- NIH award 3R41HG008118-01A1S1 FY2016: $18,926 awarded for that fiscal year; activity R41 (STTR); PI HEINTZMAN, NATE; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Optimizing HaploSeq for whole-genome phas source ↗
- NIH award 1R41HG008118-01A1 FY2015: $349,961 awarded for that fiscal year; activity R41 (STTR); PI HEINTZMAN, NATE; recipient as written: ARIMA GENOMICS, LLC, SAN DIEGO, CA. Optimizing HaploSeq for whole-genome phase source ↗